Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NYSE:BHVN

Biohaven Q3 2026 Earnings Date & Estimates

Biohaven logo
$11.46 -0.36 (-3.01%)
Closing price 03:59 PM Eastern
Extended Trading
$11.50 +0.05 (+0.40%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biohaven is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biohaven in Q3 2026

Biohaven is expected to post earnings of -$0.6097 per share on revenue of $70.00 million. In the same quarter a year earlier Biohaven reported -$1.64 per share. Biohaven last reported on August 10, 2026, posting -$0.91 per share and missing the -$0.7610 consensus estimate. Biohaven has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6097
Expected Revenue
$70.00 million
Prior-Year EPS
-$1.64

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.91 (Missed by -$0.1490)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Biohaven Q3 2026 Earnings FAQ

Biohaven (NYSE:BHVN) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Biohaven's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biohaven to post earnings of -$0.6097 per share for Q3 2026.

The consensus revenue estimate for Biohaven is $70.00 million for Q3 2026.

Biohaven Earnings Headlines

Stocktwits biotech dealmaker — Viatris and GE Healthcare buy what they can sell; Biohaven and Alector sell rights
October 9, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/stocktwits-biotech-dealmaker-viatris-and-ge-healthcare-buy-what-they-can-sell-biohaven-and-alector-sell-rights/ar-AA2dVzsY
Biohaven, Ono Pharma Partner on $100 Million Autoimmune Disease Treatment License in Asia
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biohaven-ono-pharma-partner-100-083945296.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 13 at 1:00 AM  |  Base Camp Trading (Ad)
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
October 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohaven-enters-strategic-licensing-agreement-with-ono-pharma-for-extracellular-igg-degraders-in-japan-and-select-asian-regions-lead-candidate-bhv-1300-in-phase-3-for-graves-disease-302901852.html
Biohaven Ltd. (NYSE:BHVN) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
October 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097942
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
September 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biohavens-clinical-data-on-bhv-1530-a-novel-fgfr3-directed-adc-with-a-proprietary-topoisomerase-i-topoix-payload-selected-for-oral-presentation-at-the-eortc-nci-aacr-symposium-2026-302890885.html
See More Biohaven Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email.

About Biohaven

Biohaven (NYSE:BHVN) (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways. Its research programs span both clinical-stage and earlier-stage candidates, although the status and indications of individual programs may change as development progresses.

The company was originally known as Biohaven Pharmaceutical Holding Company and developed the migraine medicines Nurtec ODT and Zavzpret. Pfizer acquired Biohaven’s commercial CGRP migraine portfolio in 2022, while the current Biohaven Ltd. retained and continued developing a separate pipeline of investigational medicines. Biohaven is headquartered in New Haven, Connecticut, and its operations and clinical-development activities serve patients and research markets internationally. Vlad Coric has served as the company’s chief executive officer.

View Biohaven Profile
Earnings Tools